Table 3.

Final model of predictors of TNF inhibitor discontinuation.

	Combined Model*		Combined Model (backward selection)		Combined Model (backward selection) with Age and Gender
	Hazard Ratio†	95% CI	Hazard Ratio†	95% CI	Hazard Ratio†	95% CI
Physical activity**	0.98	0.95–1.01
Hispanic	1.44	0.70–2.98
Prior synthetic DMARD	0.48	0.33–0.71	0.43	0.30–0.62	0.50	0.34–0.72
No. prior TNF inhibitors	1.42	1.08–1.82	1.35	1.06–1.72	1.30	1.03–1.66
Concomitant methotrexate	1.54	1.06–2.25	1.70	1.19–2.43	1.57	1.09–2.25
Cumulative methotrexate	0.23	0.11–0.47	0.20	0.10–0.41	0.24	0.12–0.47
Baseline RADAI††	1.00	0.92–1.08
Baseline physician global††	1.01	0.92–1.10
End RADAI††	1.14	1.03–1.25	1.11	1.03–1.20	1.13	1.05–1.22
End physician global††	1.26	1.15–1.38	1.25	1.15–1.35	1.27	1.18–1.38
Fatigue	1.00	0.99–1.00
Age, yrs, continuous	0.99	0.98–1.00			0.99	0.98–1.01
Female gender	0.97	0.65–1.45			1.04	0.70–1.53
Disease duration	0.99	0.98–1.00			0.99	0.97–1.00

^*Variables identified in domain-specific multivariate analyses using p < 0.05

^**MET hours per week.

^†HR > 1.0 indicates more likely to discontinue TNF inhibitor.

^††Per point.